Currently Viewing:
The American Journal of Managed Care September 2016
Implications of Evolving Delivery System Reforms for Prostate Cancer Care
Brent K. Hollenbeck, MD, MS; Maggie J. Bierlein, MS; Samuel R. Kaufman, MS; Lindsey Herrel, MD; Ted A. Skolarus, MD, MPH; David C. Miller, MD, MPH; and Vahakn B. Shahinian, MD
New Strategies for Aligning Physicians With Health System Incentives
Amol S. Navathe, MD, PhD; Aditi P. Sen, MA; Meredith B. Rosenthal, PhD; Robert M. Pearl, MD; Peter A. Ubel, MD; Ezekiel J. Emanuel, MD, PhD; Kevin G. Volpp, MD, PhD
Cost-Benefit of Appointment-Based Medication Synchronization in Community Pharmacies
Julie A. Patterson, BS; David A. Holdford, PhD, MS, BSPharm; and Kunal Saxena, PhD, MS
Geographic Variation in Surgical Outcomes and Cost Between the United States and Japan
Michael P. Hurley, MD, MS; Lena Schoemaker, BA; John M. Morton, MD, MPH; Sherry M. Wren, MD; William B. Vogt, PhD; Sachiko Watanabe, RN, MHSA, MAE; Aki Yoshikawa, PhD; and Jay Bhattacharya, MD, PhD
The Opportunities and Challenges of the MSSP ACO Program: A Report From the Field
Farzad Mostashari, MD, ScM, and Travis Broome, MPH
Managing Inappropriate Requests of Laboratory Tests: From Detection to Monitoring
Maria Salinas, PhD; Maite López-Garrigós, PhD; Emilio Flores, PhD; Maria Leiva-Salinas, MD, PhD; Alberto Asencio, MD; Javier Lugo, MD; and Carlos Leiva-Salinas, MD, PhD
Measuring the Cost Implications of the Collaborative Accountable Care Initiative in Texas
Vivian Ho, PhD; Timothy K. Allen, PhD; Urie Kim, BBA; William P. Keenan, BA; Meei-Hsiang Ku-Goto, MA; and Mark Sanderson, PhD
Knowledge Gaps Inhibit Health IT Development for Coordinating Complex Patients' Care
Robert S. Rudin, PhD; Eric C. Schneider, MD, MSc; Zachary Predmore, BA; and Courtney A. Gidengil, MD, MPH
Currently Reading
Mapping US Commercial Payers' Coverage Policies for Medical Interventions
James D. Chambers, PhD; Matthew D. Chenoweth, MPH; and Peter J. Neumann, ScD

Mapping US Commercial Payers' Coverage Policies for Medical Interventions

James D. Chambers, PhD; Matthew D. Chenoweth, MPH; and Peter J. Neumann, ScD
The authors examine the largest 20 US commercial payers’ coverage policies and identify variation in how interventions are covered and the evidence reviewed in them.
ABSTRACT

Objectives:
To examine coverage policies for medical interventions issued by the largest US commercial payers.

Study Design: Review of publicly accessible coverage policies for medical interventions.

Methods: We categorized the 20 largest commercial payers’ medical benefit coverage policies for medical technologies—current as of August 1, 2014—with respect to technology type (eg, medical devices, pharmaceuticals, surgeries). We identified the interventions most commonly subject to coverage policies and compared payer coverage determinations in terms of whether they covered the intervention and the evidence they reported reviewing. 

Results: Eighteen payers made their coverage policies publicly available and 17 reported the evidence they reviewed in formulating policies. The types of technologies considered varied across payers, although most focused on devices and diagnostics. Of the 28 interventions most commonly subject to coverage policies, the coverage of 9 varied (ie, some payers covered the intervention and others did not). On average, payers reported reviewing clinical studies in 87% of coverage policies (range = 25%-100%). Two payers did not report reviewing systematic reviews or meta-analyses in any coverage policies, and 9 reported reviewing such evidence in at least half of their policies. Fourteen payers reported reviewing cost-effectiveness analyses at least some of the time, with frequency ranging from 8% to 43%. Commercial payers’ coverage decisions did not appear to reflect direct input from patients or patient advocates, at least as stated in published coverage policies.

Conclusions: Coverage of medical interventions varies across US private payers. Payers often report reviewing different evidence when formulating coverage policies, but do not report considering input directly from patients in evidence assessments.

Am J Manag Care. 2016;22(9):e323-e328
This paper identifies important variation in the largest commercial payers’ coverage policies for medical interventions. We found: 
  • Payers vary with respect to both the number of coverage policies they issue and the types of medical interventions they issue policies for. 
  • There is much variation in how payers cover medical interventions, meaning that patients in one insurance plan will have access to an intervention, but patients in another plan may not. 
  • Payers often report reviewing different evidence when formulating coverage policies, but no payer reported considering input specifically from patients.
In US healthcare, multiple public and commercial payers issue coverage policies for medical interventions.1-3 Because payers conduct their own assessments and issue their own decisions, whether and how they cover medical interventions can vary, which, in turn, can affect patients’ access to care. Researchers have highlighted variation in payer coverage policies and examined decision making.4,5 Recent research has studied trends in Medicare National Coverage Determinations (NCDs) and the consistency of coverage with the reviewed evidence.6-8 Another recent study found substantial variation in how Medicare and private payers cover medical devices.9

This study adds to the literature by examining coverage policies for medical interventions issued by the top 20 US commercial payers. First, we examined the coverage policies issued by the largest US-based commercial payers. Second, for a representative set of interventions, we compared coverage determinations across payers (ie, whether and how the payers cover the interventions and the types of evidence the payers reported reviewing when formulating their policies).

METHODS

We identified the 20 largest US-based commercial payers in terms of number of covered lives.10 We searched each payer’s website to determine the availability of their medical benefit coverage policies. In many cases, payers provide memoranda, which describe the target patient population, any conditions on patient access to an intervention, and, frequently, the clinical trials, clinical guidelines, and other evidence the payer reports reviewing when formulating the coverage policy. We focused on coverage policies pertaining to the payers’ commercial line of business by excluding coverage policies pertaining to their Medicaid managed care or Medicare Advantage lines of business. When we were unable to locate memoranda, we contacted the payer to confirm their unavailability.

We identified all coverage policies issued by each of the 20 payers (n = 7372). Included policies were current as of August 1, 2014. We categorized each policy with respect to intervention type (eg, medical device, pharmaceutical, surgery, diagnostic imaging); categories were not mutually exclusive (eg, we included implantable cardiac defibrillators and artificial lumbar disc replacement in both the medical device and surgery categories). 

Comparison of Payers’ Coverage Determinations for a Representative Set of Interventions

We determined the 4 intervention types that accounted for the majority of coverage policies: medical devices, pharmaceuticals, surgeries, and diagnostic tests/imaging procedures. For each, we identified the 7 interventions for which the payers most often issued coverage policies (Table 1). We included 7 interventions of each type to ensure they were adequately represented across the payers. We used this representative set of 28 interventions to determine whether the payers covered the interventions and the types of evidence payers report reviewing in their policies.

We considered whether the payers reported reviewing 1 or more of the following 6 evidence types: clinical studies (eg, randomized controlled trials or observational studies), systematic literature reviews or meta-analyses, technology assessments, cost-effectiveness analyses, budget impact analyses, and clinical guidelines. A researcher read the coverage policies to determine whether payers cited each evidence type. The researcher then searched each policy for pertinent keywords; for example, when searching for cost-effectiveness analyses, the researcher searched for the terms, “cost-effectiveness,” “economic evaluation,” “cost-benefit,” and so on. We also determined whether coverage decisions reflected input from patients (eg, whether comments from patients or patient advocacy organizations were accounted for).

RESULTS

Wide Variation in the Number of Coverage Policies That Payers Issue

Eighteen of 20 of the largest commercial payers made their medical benefit coverage policies publicly available (Kaiser Permanente and Centene Corporation were the exceptions). The number of policies payers issued varied, from 146 by UnitedHealthcare to 698 by Aetna. Eighty-nine percent of payers issued the largest proportion of their coverage policies for medical devices; 11% issued the largest proportion for drugs (Table 2).

How Payers Cover Medical Technology Often Varies

Payers covered the representative set of interventions with different frequencies (eAppendix, available at www.ajmc.com). Highmark most often covered the interventions we examined (20 of the 23 interventions for which Highmark issued a coverage policy; 87%). Blue Shield of California least often covered the interventions (11 of 21; 52%) (Table 3).

Sixteen interventions in the representative set were covered by all the payers that issued a coverage policy for it (eg, cryosurgical ablation for prostate cancer). Three interventions in the set were not covered by any payer (eg, biochemical markers for Alzheimer’s disease). The remaining 9 interventions in the set were covered by some payers but not others; for example, of the 11 payers that issued a coverage policy for microvolt t-wave alternans testing to identify patients at risk of sudden cardiac arrest, 5 covered the technology and 6 did not.

The Types of Evidence Payers Report Reviewing in Their Coverage Policies Varies

The types of evidence that payers report reviewing in their coverage policies for interventions in the representative set varied. On average, the 17 payers that reported the evidence they reviewed cited clinical studies in 87% of coverage policies (range = 25%-100%).

Payers reported evaluating systematic reviews and meta-analyses with different frequencies. Two payers did not report reviewing systematic reviews or meta-analyses in any of their coverage policies; the remaining 15 payers did so in an average of 50% of their coverage policies (range = 22%-89%). Payers also report reviewing cost-effectiveness analyses with different frequencies. Three payers did not report reviewing cost-effectiveness analyses in their coverage policies; the remaining 14 payers did so in an average of 14% of their coverage policies (range = 8%-43%). Four payers reported reviewing a budget impact analysis in one of their coverage policies for interventions in the representative set (Table 3).

Each payer reported reviewing clinical guidelines and did so in an average of 80% of their coverage policies (range = 62%-100%). Each payer reported reviewing technology assessments in a proportion of their coverage policies and did so in an average of 60% of their coverage policies (range = 22%-89%).

Coverage Policies Did Not Directly Reflect Patient Input

We found no indication of payers having a formal process for including patients and/or consumer input into decision making. Furthermore, we found that no payers reported accounting for patient input (ie, from patients or patient advocacy organizations) in the evidence base they reported reviewing (Table 3).

DISCUSSION

Although researchers have previously examined variation in commercial payer coverage policies, this study is unique in describing the coverage policies issued by the largest US-based commercial payers.9,11-13 Our study highlights several points. 

Coverage Policy Practices Among the Largest US Commercial Payers Varies

We found wide variation in the number of coverage policies promulgated by the largest commercial payers. Why some payers are more selective than others in this regard is unclear. The administrative burden of maintaining a large number of up-to-date coverage policies may lead payers to restrict those they make publicly available to big-ticket technologies or interventions for which patients’ access is most ambiguous. Some payers may believe that limiting the number of publicly available policies affords them greater flexibility and allows them to more rapidly respond to new evidence or changing circumstances. Patients, however, may benefit from having more access to information about coverage of medical interventions.

Payers Often Cover Interventions Differently

We found that for the representative set of interventions, payers’ coverage determinations often varied. Discrepancies could possibly be attributable to payers differentially weighing factors (eg, the influence of local physicians) in their decision making. Payers may interpret the supporting evidence-base differently or differentially weigh product price, value, and budget impact in decision making. Differences in how payers cover interventions may also be influenced by contractual language and/or state mandates. Interestingly, we found variation in the coverage policies issued by plans in our sample that are part of the Blue Cross Blue Shield Association. This variation suggests that despite having access to Blue Cross Blue Shield national model policies, the plans independently modify the policies to meet their own standards and priorities on occasion.

The differences among coverage policies suggest that patients may have differential access to medical interventions that, in turn, may lead to variation in health outcomes.5 Differences between payer-covered benefits may also impact provider behavior, as physicians may tailor patient care to insurance coverage. However, variation among payer coverage determinations may have some salutatory effects if payers’ coverage policies reflect their enrollees’ unique characteristics.14 

Payers Report Using Different Evidence in Coverage Determinations

The evidence that payers reported reviewing in their coverage policies varied. As expected, we found that clinical evidence and clinical guidelines featured prominently in the payers’ evidence review. Technology assessments also commonly featured in the reviewed coverage policies. In contrast, review of systematic reviews or meta-analyses and economic studies varied considerably. Notably, the majority of payers reported reviewing cost-effectiveness analyses in at least some of the representative set of coverage policies, presumably reflecting the continued introduction of high-cost treatments.15 Few payers reported reviewing budget impact analyses.

A greater appreciation of payers’ use of evidence could help providers understand how patients’ benefit packages are designed. It is essential for manufacturers to understand the role of evidence in coverage policies as they design clinical development programs to demonstrate the efficacy, safety, and value of their products.

The Patient Voice in Coverage Determinations Is Lacking

We found that payers did not report considering input from patients in their coverage policies. This finding is at odds with recent initiatives that seek to emphasize the patient perspective in the drug approval process and evidence generation.16-18 This finding is also inconsistent with other countries’ health technology assessment agencies that engage with the public at various levels of decision making.19-23

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!